招财日报2025.9.4 维立志博首予买入/中国人寿、JS环球业绩点评

招银国际
Sep 04, 2025

公司点评维立志博(9887 HK,首次覆盖-买入,目标价:80.27港元)- 开发下一代免疫肿瘤治疗药物覆盖免疫检查点、T细胞衔接器及ADC的广泛产品管线。维立志博专注于开发以免疫检查点为基础的免疫治疗药物,包括共刺激激动剂和检查点抑制剂,并积极拓展至CD3 T细胞衔接器和ADC等领域。公司已建立自主研发的LeadsBody平台(CD3 T细胞衔接器平台)和X-body平台(4-1BB激动剂平台)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10